Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   ACTAVIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-23
ACTAVIS
Dec-18
SUN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,07216,037-   
Low Rs79010,758-   
Sales per share (Unadj.) Rs182.93,933.9-  
Earnings per share (Unadj.) Rs35.7-1,267.1-  
Cash flow per share (Unadj.) Rs46.2414.5-  
Dividends per share (Unadj.) Rs11.500-  
Avg Dividend yield %1.20-  
Book value per share (Unadj.) Rs233.416,225.6-  
Shares outstanding (eoy) m2,399.34332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.13.4 149.4%   
Avg P/E ratio x26.1-10.6 -246.7%  
P/CF ratio (eoy) x20.132.3 62.3%  
Price / Book Value ratio x4.00.8 483.0%  
Dividend payout %32.20-   
Avg Mkt Cap Rs m2,233,3614,456,026 50.1%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m82,9600-   
Avg. sales/employee Rs Th077,421.7-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-24,937.6-  
INCOME DATA
Net Sales Rs m438,8571,308,427 33.5%  
Other income Rs m8,19925,021 32.8%   
Total revenues Rs m447,0551,333,448 33.5%   
Gross profit Rs m112,90034,287 329.3%  
Depreciation Rs m25,294559,324 4.5%   
Interest Rs m1,72075,504 2.3%   
Profit before tax Rs m94,084-575,519 -16.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0146,780 0.0%   
Tax Rs m8,476-7,293 -116.2%   
Profit after tax Rs m85,608-421,445 -20.3%  
Gross profit margin %25.72.6 981.7%  
Effective tax rate %9.01.3 710.9%   
Net profit margin %19.5-32.2 -60.6%  
BALANCE SHEET DATA
Current assets Rs m398,619536,648 74.3%   
Current liabilities Rs m199,064474,737 41.9%   
Net working cap to sales %45.54.7 961.0%  
Current ratio x2.01.1 177.1%  
Inventory Days Days14720 750.7%  
Debtors Days Days9566 143.5%  
Net fixed assets Rs m376,960148,107 254.5%   
Share capital Rs m2,3990-   
"Free" reserves Rs m557,5550-   
Net worth Rs m559,9545,396,648 10.4%   
Long term debt Rs m01,900,356 0.0%   
Total assets Rs m775,7948,436,189 9.2%  
Interest coverage x55.7-6.6 -841.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.2 364.7%   
Return on assets %11.3-4.1 -274.5%  
Return on equity %15.3-7.8 -195.8%  
Return on capital %17.1-4.8 -353.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m82,5410-   
CASH FLOW
From Operations Rs m49,593467,451 10.6%  
From Investments Rs m-79,437256,804 -30.9%  
From Financial Activity Rs m23,761-802,287 -3.0%  
Net Cashflow Rs m1,155-77,642 -1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: SHAMROCK IND  MERCURY LAB.  HIKAL.  PHAARMASIA  IND SWIFT LA  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.